4-Hydroxymethyl-3-chinuclidinon | 5291-28-1

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 奎宁环
• 英文名称: 4-Hydroxymethyl-3-chinuclidinon
• 英文别名: 4-hydroxymethyl-1-aza-bicyclo[2.2.2]octan-3-one；4-(Hydroxymethyl)quinuclidin-3-one；4-(hydroxymethyl)-1-azabicyclo[2.2.2]octan-3-one
• CAS: 5291-28-1
• 化学式: C₈H₁₃NO₂
• 分子量: 155.197
• InChiKey: HFUPPJKZSZZATR-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0
• 重原子数：
  11
• 可旋转键数：
  1
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.88
• 拓扑面积：
  40.5
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  quinuclidin-4-ylmethyl-1H-indole-3-carboxylate 、 4-Hydroxymethyl-3-chinuclidinon 生成 (3-oxoquinuclidin-4-yl)methyl 1H-indole-3-carboxylate
  参考文献：
  名称：

  4-substituted quinuclidine derivatives, methods of production, pharmaceutical uses thereof

  摘要：

  本发明涉及能够影响尼古丁乙酰胆碱受体(nAChRs)的化合物和配方，例如，作为特定尼古丁受体亚型（特别是α7 nAChR亚型）的调节剂。本发明还涉及治疗各种疾病和障碍的方法，特别是那些与中枢和自主神经系统功能障碍有关的。

  公开号：

  US08114891B2

文献信息

• 4-SUBSTITUTED QUINUCLIDINE DERIVATIVES, METHODS OF PRODUCTION, AND PHARMACEUTICAL USES THEREOF
  申请人：Pfister Jurg R.

  公开号：US20090088418A1

  公开（公告）日：2009-04-02

  The present invention relates to compounds and formulations capable of affecting nicotinic acetylcholine receptors (nAChRs), for example, as modulators of specific nicotinic receptor subtypes (specifically, the alpha7 nAChR subtype). The present invention also relates to methods for treating a wide variety of conditions and disorders, particularly those associated with dysfunction of the central and autonomic nervous systems.

  本发明涉及影响尼古丁乙酰胆碱受体（nAChRs）的化合物和配方，例如，作为特定尼古丁受体亚型（具体来说是α7 nAChR亚型）的调节剂。本发明还涉及用于治疗各种疾病和紊乱的方法，特别是与中枢和自主神经系统功能障碍相关的疾病。
• QUINUCLIDIN-4-YLMETHYL 1H-INDOLE-3-CARBOXYLATE DERIVATIVES AS ALPHA 7 NICOTINIC ACETYLCHOLINE RECEPTOR LIGANDS FOR THE TREATMENT OF ALZHEIMER'S DISEASE
  申请人：COMENTIS, INC.

  公开号：EP2217597A1

  公开（公告）日：2010-08-18
• US8114891B2
  申请人：——

  公开号：US8114891B2

  公开（公告）日：2012-02-14
• [EN] QUINUCLIDIN-4-YLMETHYL 1H-INDOLE-3-CARBOXYLATE DERIVATIVES AS ALPHA 7 NICOTINIC ACETYLCHOLINE RECEPTOR LIGANDS FOR THE TREATMENT OF ALZHEIMER'S DISEASE<br/>[FR] DÉRIVÉS DE QUINUCLIDINE SUBSTITUÉ EN POSITION 4, PROCÉDÉS DE PRODUCTION ET UTILISATIONS PHARMACEUTIQUES DE CEUX-CI
  申请人：COMENTIS INC

  公开号：WO2009046025A1

  公开（公告）日：2009-04-09

  The present invention relates to compounds and formulations capable of affecting nicotinic acetylcholine receptors (nAChRs), for example, as modulators of specific nicotinic receptor subtypes (specifically, the alpha7 nAChR subtype). The present invention also relates to methods for treating a wide variety of conditions and disorders, particularly those associated with dysfunction of the central and autonomic nervous systems.